K36 Therapeutics Announces Multiple Poster Presentations Highlighting the First Clinical Data for KTX-1001 and Other Developmental Compounds at the 66th American Society of Hematology (ASH...
K36 Therapeutics Announces Presentation on KTX-1001 for Relapsed and Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting PR Newswire CAMBRIDGE, Mass., Dec...
MONTREAL, June 25, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF), a leading specialty pharmaceutical company with a strong North...
Amcor Finance (USA), Inc. And Bemis Company, Inc. Announce Extension Of Exchange Offers And Consent Solicitations For US$2.2 Billion Of Notes PR Newswire ZURICH and NEENAH, Wis., June 5, 2019...
Bemis Set to Join S&P 500; Mattel to Join S&P MidCap 400 PR Newswire NEW YORK, June 3, 2019 NEW YORK, June 3, 2019 /PRNewswire/ -- S&P MidCap 400 constituent Bemis Company Inc. (NYSE:...
Amcor Limited (ASX: AMC) and Bemis Company, Inc. (NYSE: BMS) announce that regulatory clearance has been received from the US Department of Justice in relation to the combination of the two...
Amcor Finance (USA), Inc. And Bemis Company, Inc. Announce Results Of Early Tenders In Exchange Offers And Consent Solicitations For US$2.2 Billion Of Notes PR Newswire ZURICH and NEENAH, Wis...
Amcor Finance (USA), Inc. And Bemis Company, Inc. Announce Exchange Offers And Consent Solicitations For US$2.2 Billion Of Notes PR Newswire ZURICH and NEENAH, Wis., May 8, 2019 ZURICH and...
Amcor Limited (ASX: AMC) and Bemis Company, Inc. (NYSE: BMS) have made significant progress towards closing the all-stock transaction announced on 6 August 2018. All clearances and consents...
Bemis Company, Inc. (NYSE: BMS) today announced that its shareholders voted to approve Bemis’ combination with Amcor Limited (ASX: AMC) at the Company’s Special Meeting of Shareholders held...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales